Target | Drug | Combination agent | Phase | Tumor type | Clinical efficacy | PFS(m) | OS(m) | Safety | NCT Number | Status |
---|---|---|---|---|---|---|---|---|---|---|
FAP | 68Ga-FAP-2286 | - | Phase 1 | Metastatic solid cancer | - | - | - | - | NCT04621435 | Recruiting |
68Ga-FAPI-04 | - | Phase 2 | Epithelial ovarian cancer | - | - | - | - | NCT04504110 | Unknown | |
- | Phase 1 | Various cancer types | - | - | - | - | NCT04459273 | Recruiting | ||
[18F] FAPI-74 PET/CT | - | Phase 2 | Gastrointestinal cancer | - | - | - | - | NCT05641896 | Recruiting | |
RO6874281 | Trastuzumab or cetuximab | Phase 1 | BC and HNC | - | - | - | - | NCT02627274 | Completed | |
AVA6000 | - | Phase 1 | Various solid tumors | - | - | - | - | NCT04969835 | Recruiting | |
Re-directed T cells | - | Phase 1 | MPM | - | - | - | - | NCT01722149 | Completed | |
BXCL701 | Pembrolizumab | Phase 1Phase 2 | Prostate cancer | - | - | - | - | NCT03910660 | Active, not recruiting | |
Pembrolizumab | Phase 2 | Metastatic PDAC | - | - | - | - | NCT05558982 | Not yet recruiting | ||
CXCR4 | AMD3100 | Cemiplimab | Phase 2 | Metastatic PAC | - | - | - | - | NCT04177810 | Completed |
BMS-936564 | Nivolumab | Phase 1 Phase 2 | PAC and SCLC | - | - | - | Serious adverse events: 31/41 Immune-mediated adverse events:4/41 | NCT02472977 | Terminated | |
BL-8040 | Pembrolizumab | Phase 2 | Metastatic PAC | In cohort 1, the DCR was 34.5% in the evaluable population (modified intention to treat, mITT; N = 29), including nine patients (31%) with stable disease and one patient (3.4%) with partial response. In cohort 2, 22 patients received BL-8040 and pembrolizumab with chemotherapy, with an ORR, DCR, and median duration of response of 32%, 77%, and 7.8 months, respectively. | - | 3.3 months in cohort 1 | A total of 37 patients were enrolled in cohort 1, the most common adverse event was mild to moderate injection site reaction. Only one patient (2.7%) had permanent discontinuation of study drugs owing to treatment-related adverse events (pain and pruritus at the injection site), and no treatment-related deaths were observed | NCT02826486 | Completed | |
Cemiplimab, gemcitabine and nab-paclitaxel | Phase 2 | Pancreas adenocarcinoma | - | - | - | - | NCT04543071 | Recruiting | ||
MSX-122 | - | Phase 1 | Refractory metastatic or locally advanced solid tumors | - | - | - | - | NCT00591682 | Suspended | |
POL6326 | Eribulin | Phase 1 | Metastatic BC | Objective responses (all partial responses) were observed in 16 (30%; 95% CI 18–44) of 54 patients who were evaluable for antitumour activity. | 4.6 months (95%CI 3.1–5.7) in the overall efficacy population. | - | The most common treatment-emergent adverse events of any grade were fatigue (44 [79%] of 56 patients), neutropenia (32 [57%]), infusion-related reactions (27 [48%]), alopecia (26 [46%]), constipation (26 [46%]), and nausea (25 [45%]). Serious adverse events occurred in 21 (38%) of 56 patients, including febrile neutropenia in five (9%) of 56 patients, neutrophil count decrease in two (4%) patients, constipation in two (4%) patients, pneumonia in two (4%) patients, and urinary tract infection in three (5%) patients. Two (4%) of 56 patients died while receiving study treatment; one from septic shock and one from pneumonia. | NCT01837095 | Completed | |
TGF-β and PD-L1 | M7824 | - | Phase 1 | Stage II-III HER2 positive breast cancer | - | - | - | - | NCT03620201 | Active, not recruiting |
SAR439459 | Cemiplimab | Phase 1 | Malignant solid tumor | - | - | - | - | NCT03192345 | Terminated | |
Cemiplimab | Phase 1 | Advanced or unresectable solid tumor | - | - | - | - | NCT04729725 | Terminated | ||
TEW-7197 | Durvalumab | Phase 2 | Urothelial cancer | - | - | - | - | NCT04064190 | Not yet recruiting | |
LY2157299 | Nivolumab | Phase 1 Phase 2 | Advanced refractory solid tumors, recurrent or refractory NSCLC, or HCC | In phase 2, researchers provide the date on ORR, ORR of galunisertib + nivolumab (NSCLC) group and galunisertib + nivolumab (HCC) group was 24% and 0% | In phase 2, researchers provide the date on mPFS, mPFS of galunisertib + nivolumab (NSCLC) group and galunisertib + nivolumab (HCC) group was 5.62 months and 5.39 months | In phase 2, researchers provide the date on mOS, mOS of galunisertib + nivolumab (NSCLC) group and galunisertib + nivolumab (HCC) group was 11.99 months and 14.52 months | Serious adverse events: 19/41 | NCT02423343 | Completed | |
TGF-β | Galunisertib | Paclitaxel | Phase 1 | Metastatic androgen receptor negative (AR-) triple negative BC | - | - | - | - | NCT02672475 | Active, not recruiting |
Fresolimumab | - | Phase 2 | Metastatic BC | Abscopal response rate 100% for group: Fresolimumab 1 mg/kg and group; Fresolimumab 10 mg/kg | - | Arm 1: 7.57 months; arm 2: 16.0 months | Serious adverse events 3/11 for group: Fresolimumab 1 mg/kg and 3/12 for Fresolimumab 10 mg/kg | NCT01401062 | Completed | |
LY3200882 | Capecitabine | Phase 1 Phase 2 | Advanced resistant TGF-beta activated CRC | - | - | - | - | NCT04031872 | Unknown | |
HSP90 | XL888 | Pembrolizumab | Phase 1 | Advanced gastrointestinal cancer | - | - | - | - | NCT03095781 | Active, not recruiting |
Hedgehog | Sonidegib | Gemcitabine and nab paclitaxel | Phase 1 Phase 2 | Pancreatic cancer | PR 13%, SD 58%, and PD 29% | - | 6 | six therapy-related grade 4 AEs and three grade 5 were observed | NCT02358161 | Completed |
Vitamin A | ATRA | Gemcitabine and nab-paclitaxel | Phase 2 | Locally advanced PDAC | - | - | - | - | NCT04241276 | Recruiting |
HDAC, PI3K/AKT | CUDC-907 | - | Phase 1 | Advanced/relapsed solid tumors | - | - | - | - | NCT02307240 | Completed |
STAT3 | BBI608 | Paclitaxel | Phase 3 | Non-squamous NSCLC | - | - | - | - | NCT02826161 | Terminated |
Gemcitabine and nab-paclitaxel | Phase 3 | Metastatic PDAC | DCR among napabucasin-treated and control-treated patients was 74.5% and 76.0%, respectively, and ORR was 43.2% and 42.9%, respectively | Napabucasin-treated group: 6.7 months, control-treated group: 6.1 months | Napabucasin-treated group: 11.4 months, control-treated group: 11.7 months | The most common AEs among napabucasin-treated and control-treated patients were diarrhoea (73.1% vs 38.9%), nausea (58.6% vs 46.1%), and anaemia (54.5% vs 58.1%). Serious AEs were reported in 58.8% of patients treated with napabucasin plus nab-paclitaxel with gemcitabine and 49.9% of those administered nab-paclitaxel with gemcitabine alone | NCT02993731 | Completed | ||
BBI503 or BBI608 | Sorafenib | Phase 1 Phase 2 | HCC | Researchers provided data on ORR and DCR in phase 2 study. ORR based on RECIST 1.1 criteria among three arms was 3.6% (95%CI 0.1%-18.3%), 0 (95%CI 0-30.8%), 9.7% (95%CI 2%-25.8%), respectively. DCR based on RECIST 1.1 criteria among three arms was 35.7% (95%CI 18.6%-55.9%), 70% (95%CI 34.8%-93.3%), 48.4% (95%CI 30.2%-66.9%), respectively. | - | - | Serious adverse events: 39/91 | NCT02279719 | Completed | |
Paclitaxel | Phase 1Phase 2 | Advanced malignancies | Researchers provided data on ORR and DCR. ORR among five arms was 0%, 28.4%, 0%, 9.2% and 20.7%, respectively; DCR among five arms was 100%, 53.1%, 0%, 56.1% and 51.7%, respectively | Researchers provided data on mPFS, mPFS among five arms was NA, 2.23 months, NA, 2.07 months and 2.3 months, respectively | Researchers provided data on mOS, mOS among five arms was NA, 7.79 months, NA, 2.07 months and 2.3 months, respectively | Serious adverse events: 53/565 | NCT01325441 | Completed | ||
LRRC15 | ABBV-085 | - | Phase1 | Advanced solid tumors | In the “all sarcomas at all doses” population the ORR was 10.8%. In the patients with osteosarcoma or UPS treated at the 3.6 mg/kg dose the ORR was 20%. Among patients with UPS treated at 3.6 mg/kg, four patients had PR with tumor shrinkage of >30% | - | - | Most common treatment-related adverse events were fatigue, nausea, and decreased appetite | NCT02565758 | Completed |
Hyaluronic acid | PEGPH20 | Avelumab | Early Phase 1 | Chemotherapy resistant PAC | - | - | - | - | NCT03481920 | Terminated |
BET | GSK525762 | - | Phase 1 | NUT midline carcinoma and other cancers | Among 19 patients with NC, four achieved either confirmed or unconfirmed partial response, eight had stable disease as best response, and four were progression-free for more than 6 months. | Median PFS for the NC cohort was 2.5 months (95% confidence interval = 0.5 to 3.7 months). | - | The most frequent treatment-related adverse events of any grade were thrombocytopenia (51%) and gastrointestinal events, including nausea, vomiting, diarrhea, decreased appetite, and dysgeusia (22%–42%), anemia (22%), and fatigue (20%). | NCT01587703 | Completed |
ErbB3 | MM-121 | - | Phase 1 | Advanced solid tumors | ORR was 0% | Median PFS estimate was 7.1 (95% CI: 4.7‒7.4) weeks in the dose escalation and 7.1 (95% CI: 6.6‒15.9) weeks in the dose expansion portion of the study | - | The most common TEAEs related to seribantumab were nausea (44%), diarrhea (36%), fatigue (28%), and skin rash (24%). No infusion-related reactions or dose-dependency were observed. Serious adverse events (SAEs) occurred in 24% (6/25) of patients in the dose escalation portion | NCT00734305 | Completed |
HER3 | Seribantumab | - | Phase 2 | NRG1 gene fusion positive advanced solid tumors | - | - | - | - | NCT04383210 | Active, not recruiting |
RTKs | Regorafenib | - | Phase 2 | Gastric or gastroesophagel Junction Cancer | - | - | - | - | NCT03627728 | Recruiting |
Nivolumab | Phase 3 | Gastro-oesophageal cancer | - | - | - | - | NCT04879368 | Recruiting | ||
- | Gemcitabine | PEGPH20 and placebo | Phase 1 Phase 2 | Stage IV Pancreatic Cancer | PEGPH20 1.0 μg/kg group: ORR=0% and DCR=25% PEGPH20 1.6 μg/kg group: ORR=50% and DCR=100% PEGPH20 3.0 μg/kg group: ORR=40% and DCR=70% | 47 days for group: PEGPH20 1.0 μg/kg 276 days for group: PEGPH20 1.6 μg/kg 113 days for group: PEGPH20 3.0 μg/kg. | 109.5 days for group: PEGPH20 1.0 μg/kg 199.5 days for group: PEGPH20 1.6 μg/kg 220 days for group: PEGPH20 3.0 μg/kg | Serious adverse events were 2/4 for group: PEGPH20 1.0 μg/kg, 1/4 for group: PEGPH20 1.6 μg/kg, and 13/20 for group: PEGPH20 3.0 μg/kg. | NCT01453153 | Completed |